Malene Grubbe Hildebrandt1, Oke Gerke2, Christina Baun2, Kirsten Falch2, Jeanette Ansholm Hansen2, Ziba Ahangarani Farahani2, Henrik Petersen2, Lisbet Brønsro Larsen2, Sandra Duvnjak2, Inguna Buskevica2, Selma Bektas2, Katrine Søe2, Anne Marie Bak Jylling2, Marianne Ewertz2, Abass Alavi2, Poul Flemming Høilund-Carlsen2. 1. Malene Grubbe Hildebrandt, Oke Gerke, Christina Baun, Kirsten Falch, Jeanette Ansholm Hansen, Ziba Ahangarani Farahani, Henrik Petersen, Lisbet Brønsro Larsen, Sandra Duvnjak, Inguna Buskevica, Selma Bektas, Katrine Søe, Anne Marie Bak Jylling, Marianne Ewertz, and Poul Flemming Høilund-Carlsen, Odense University Hospital; Oke Gerke and Marianne Ewertz, University of Southern Denmark, Odense, Denmark; and Abass Alavi, University of Pennsylvania, Philadelphia, PA. Malene.grubbe.hildebrandt@rsyd.dk. 2. Malene Grubbe Hildebrandt, Oke Gerke, Christina Baun, Kirsten Falch, Jeanette Ansholm Hansen, Ziba Ahangarani Farahani, Henrik Petersen, Lisbet Brønsro Larsen, Sandra Duvnjak, Inguna Buskevica, Selma Bektas, Katrine Søe, Anne Marie Bak Jylling, Marianne Ewertz, and Poul Flemming Høilund-Carlsen, Odense University Hospital; Oke Gerke and Marianne Ewertz, University of Southern Denmark, Odense, Denmark; and Abass Alavi, University of Pennsylvania, Philadelphia, PA.
Abstract
PURPOSE: To prospectively investigate the diagnostic accuracy of [(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with dual-time-point imaging, contrast-enhanced CT (ceCT), and bone scintigraphy (BS) in patients with suspected breast cancer recurrence. PATIENTS AND METHODS: One hundred women with suspected recurrence of breast cancer underwent 1-hour and 3-hour FDG-PET/CT, ceCT, and BS within approximately 10 days. The study was powered to estimate the precision of the individual imaging tests. Images were visually interpreted using a four-point assessment scale, and readers were blinded to other test results. The reference standard was biopsy along with treatment decisions and clinical follow-up (median, 17 months). RESULTS: FDG-PET/CT resulted in no false negatives and fewer false positives than the other imaging techniques. Accuracy of results were similar for 1-hour and 3-hour FDG-PET/CT. For distant recurrence, the area under the receiver operating curve was 0.99 (95% CI, 0.97 to 1) for FDG-PET/CT, 0.84 (95% CI, 0.73 to 0.94) for ceCT, and 0.86 (95% CI, 0.77 to 0.94) for the combined ceCT+BS. Of 100 patients, 22 (22%) were verified with distant recurrence, and 18 of these had bone involvement. Nineteen patients (19%) had local recurrence only. In exploratory analyses, diagnostic accuracy of FDG-PET/CT was better than ceCT alone or ceCT combined with BS in diagnosing distant, bone, and local recurrence, shown by a greater area under the receiver operating curve and higher sensitivity, specificity, and superior likelihood ratios. CONCLUSION: FDG-PET/CT was accurate in diagnosing recurrence in breast cancer patients. It allowed for distant recurrence to be correctly ruled out and resulted in only a small number of false-positive cases. Exploratory findings suggest that FDG-PET/CT has greater accuracy than conventional imaging technologies in this patient group.
PURPOSE: To prospectively investigate the diagnostic accuracy of [(18)F]fluorodeoxyglucose (FDG)-positron emission tomography (PET)/computed tomography (CT) with dual-time-point imaging, contrast-enhanced CT (ceCT), and bone scintigraphy (BS) in patients with suspected breast cancer recurrence. PATIENTS AND METHODS: One hundred women with suspected recurrence of breast cancer underwent 1-hour and 3-hour FDG-PET/CT, ceCT, and BS within approximately 10 days. The study was powered to estimate the precision of the individual imaging tests. Images were visually interpreted using a four-point assessment scale, and readers were blinded to other test results. The reference standard was biopsy along with treatment decisions and clinical follow-up (median, 17 months). RESULTS:FDG-PET/CT resulted in no false negatives and fewer false positives than the other imaging techniques. Accuracy of results were similar for 1-hour and 3-hour FDG-PET/CT. For distant recurrence, the area under the receiver operating curve was 0.99 (95% CI, 0.97 to 1) for FDG-PET/CT, 0.84 (95% CI, 0.73 to 0.94) for ceCT, and 0.86 (95% CI, 0.77 to 0.94) for the combined ceCT+BS. Of 100 patients, 22 (22%) were verified with distant recurrence, and 18 of these had bone involvement. Nineteen patients (19%) had local recurrence only. In exploratory analyses, diagnostic accuracy of FDG-PET/CT was better than ceCT alone or ceCT combined with BS in diagnosing distant, bone, and local recurrence, shown by a greater area under the receiver operating curve and higher sensitivity, specificity, and superior likelihood ratios. CONCLUSION:FDG-PET/CT was accurate in diagnosing recurrence in breast cancerpatients. It allowed for distant recurrence to be correctly ruled out and resulted in only a small number of false-positive cases. Exploratory findings suggest that FDG-PET/CT has greater accuracy than conventional imaging technologies in this patient group.
Authors: Gary A Ulaner; Komal Jhaveri; Sarat Chandarlapaty; Vaios Hatzoglou; Christopher C Riedl; Jason S Lewis; Audrey Mauguen Journal: J Nucl Med Date: 2020-07-17 Impact factor: 10.057
Authors: Christopher C Riedl; Katja Pinker; Gary A Ulaner; Leonard T Ong; Pascal Baltzer; Maxine S Jochelson; Heather L McArthur; Mithat Gönen; Maura Dickler; Wolfgang A Weber Journal: Eur J Nucl Med Mol Imaging Date: 2017-05-01 Impact factor: 9.236
Authors: Julian Kirchner; Ole Martin; Lale Umutlu; Ken Herrmann; Ann-Kathrin Bittner; Oliver Hoffmann; Swetlana Mohrmann; Thomas Gauler; Sarah Theurer; Christina Antke; Irene Esposito; Sonja Kinner; Benedikt M Schaarschmidt; Bernd Kowall; Diana Lütke-Brintrup; Andreas Stang; Anton S Becker; Gerald Antoch; Christian Buchbender Journal: Eur J Radiol Date: 2020-04-24 Impact factor: 4.531